Neurocrine Biosciences, Inc.
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
About
CEO
Mr. Kyle W. Gano Ph.D.
Employees
1,700
Instrument type
Common Stock
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
MIC code
XNGS
Address
12780 El Camino Real, San Diego, CA 92130, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 28, 2025 | — | — | — | — |
| Jul 30, 2025 | — | — | — | — |
| Apr 29, 2025 | — | — | — | — |
| Feb 5, 2025 | 1.62 | — | — | — |
| Oct 30, 2024 | 1.51 | 1.24 | -0.27 | -17.88% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 7 | — | 14 |
| Average estimate | — | 1.67 | — | 7.90 |
| Low estimate | — | 0.89 | — | 6.59 |
| High estimate | — | 1.99 | — | 9.24 |
| Last year EPS | — | 1.20 | — | 6.59 |
[stock_revenue_estimate]
Growth estimates
Current qtr
25.390%
Next qtr. (Mar 2025)
38.980%
Current year
70.660%
Next year (Dec 2025)
19.890%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 1.89B | 1.49B | 1.13B | 1.05B | 788.10M |
| Cost of revenue | 39.70M | 23.20M | 14.30M | 10.10M | 7.40M |
| Gross profit | 1.85B | 1.47B | 1.12B | 1.04B | 780.70M |
| Operating expense | |||||
| Research & development | 565.00M | 463.80M | 328.10M | 275.00M | 200.00M |
| Selling general and admin | 887.60M | 752.70M | 583.30M | 433.30M | 354.10M |
| Other operating expenses | — | — | — | — | — |
| Operating income | 394.80M | 249.00M | 207.80M | 327.50M | 226.60M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 4.60M | 7.10M | 25.80M | 32.80M | 32.00M |
| Other income expense | -58.10M | -28.00M | -80.60M | -188.00M | -148.10M |
| Pretax income | 332.10M | 213.90M | 101.40M | 106.70M | 46.50M |
| Tax provision | 82.40M | 59.40M | 11.80M | -300.60M | 9.50M |
| Net income | 249.70M | 154.50M | 89.60M | 407.30M | 37.00M |
| Basic EPS | 2.56 | 1.61 | 0.95 | 4.38 | 0.40 |
| Diluted EPS | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 |
| Basic average shares | 97.70M | 95.80M | 94.60M | 93.10M | 91.60M |
| Diluted average shares | 97.70M | 95.80M | 94.60M | 93.10M | 91.60M |
| EBITDA | 416.10M | 264.60M | 218.70M | 336.10M | 234.00M |
| Net income from continuing op. | 249.70M | 154.50M | 89.60M | 407.30M | 37.00M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 3.25B | 2.37B | 2.07B | 1.73B | 1.31B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 251.10M | 262.90M | 340.80M | 187.10M | 112.30M |
| Other short term investments | 780.50M | 726.40M | 370.50M | 613.90M | 558.20M |
| Accounts receivable | 439.30M | 350.00M | 185.50M | 157.10M | 126.60M |
| Other receivables | — | — | — | — | — |
| Inventory | 38.30M | 35.10M | 30.50M | 28.00M | 17.30M |
| Prepaid assets | — | — | — | — | — |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 97.80M | 79.10M | 45.50M | 30.10M | 16.60M |
| Non current assets | |||||
| Properties | 356.10M | 145.80M | 148.80M | 122.00M | 107.80M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 36.10M | 28.20M | 24.00M | 17.60M | 15.70M |
| Construction in progress | — | — | — | — | — |
| Leases | 38.10M | 37.90M | 34.90M | 29.50M | 26.30M |
| Accumulated depreciation | -83.00M | -66.30M | -51.90M | -41.70M | -33.60M |
| Goodwill | 35.50M | 37.20M | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 35.50M | 37.20M | — | — | — |
| Investments and advances | 849.40M | 401.50M | 624.40M | 265.30M | 355.60M |
| Other non current assets | 412.20M | 330.90M | 319.50M | 325.80M | 3.20M |
| Total liabilities | 1.02B | 660.90M | 698.50M | 608.50M | 669.10M |
| Current liabilities | |||||
| Accounts payable | 108.90M | 67.30M | 51.50M | 39.40M | 41.40M |
| Accrued expenses | 90.00M | 66.60M | 61.00M | 56.50M | 30.40M |
| Short term debt | 170.10M | 169.40M | — | — | 408.80M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | 24.40M | 9.00M | — | — | — |
| Pensions | 86.20M | 72.80M | 50.60M | 38.20M | 38.90M |
| Other current liabilities | 35.90M | 20.70M | 20.00M | 17.80M | 15.20M |
| Non current liabilities | |||||
| Long term debt | 258.30M | 93.50M | 440.40M | 412.30M | 86.70M |
| Provision for risks and charges | 96.00M | 19.80M | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 10.30M | 9.90M | 12.30M | 9.70M | 17.10M |
| Shareholders equity | |||||
| Common stock | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 |
| Retained earnings | -157.10M | -406.80M | -635.80M | -725.40M | -1.13B |
| Other shareholders equity | 7.00M | -7.90M | -1.70M | 1.80M | 1.40M |
| Total shareholders equity | 2.23B | 1.71B | 1.37B | 1.13B | 636.90M |
| Additional paid in capital | 2.38B | 2.12B | 2.01B | 1.85B | 1.77B |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||||
| Net Income | 249.70M | 154.50M | 89.60M | 407.30M | 37.00M | 21.10M | -142.54M | -141.09M | -88.93M | -60.54M | -46.09M | 5.03M | 37.57M | -7.97M | -51.04M | -88.61M | -207.30M | -107.21M | -22.19M | -45.77M | -30.26M | -94.54M | -36.91M | -28.81M | -16.80M | -20.00M | 5.10M | 5.90M |
| Depreciation | 21.30M | 15.60M | 10.90M | 8.60M | 7.40M | 4.00M | 2.40M | 1.45M | 1.01M | 827,000 | 671,000 | 657,000 | 694,000 | 1.44M | 3.18M | 7.61M | 9.40M | 10.57M | 10.09M | 7.08M | 3.69M | 3.10M | 2.65M | 2.20M | 2.10M | 1.70M | 1.30M | 1.00M |
| Deferred Taxes | -56.70M | 19.10M | 4.30M | -310.70M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 194.30M | 173.10M | 134.20M | 100.00M | 75.30M | 58.10M | 42.52M | 28.46M | 28.39M | 10.38M | 6.82M | 5.48M | 2.92M | 3.13M | 5.54M | 7.99M | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | -200,000 | 1.60M | 14.30M | 25.10M | 19.10M | 19.90M | 10.34M | -878,000 | 10.13M | 14,000 | -2.78M | -32.85M | -36.51M | 65.97M | 3.63M | 13.17M | 121.81M | 7.88M | — | — | 81,000 | — | — | — | — | — | 100,000 | -100,000 |
| Accounts Receivable | -89.30M | -162.20M | -28.40M | -30.50M | -69.20M | -25.10M | -31.13M | — | — | -1.67M | 13.53M | -12.88M | 2.81M | -4.28M | 2.45M | 2.43M | 7.49M | -4.81M | 6.44M | 5.96M | -15.21M | 8.15M | -3.80M | -4.02M | -800,000 | -2.90M | 900,000 | -900,000 |
| Accounts Payable | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | 53.20M | -19.80M | -11.70M | -34.30M | 10.40M | -6.84M | -9.01M | 675,000 | -1.75M | -836,000 | -1.07M | -499,000 | -14.96M | -11.74M | -11.55M | -1.92M | -478,000 | -519,000 | 747,000 | 262,000 | — | -1.41M | -322,000 | 1.01M | -400,000 | 300,000 | -1.30M | -500,000 |
| Operating Cash Flow | 372.30M | 181.90M | 213.20M | 165.50M | 80.00M | 71.16M | -127.42M | -111.38M | -51.15M | -51.83M | -28.92M | -35.06M | -7.47M | 46.55M | -47.79M | -59.33M | -69.07M | -94.09M | -4.91M | -32.48M | -41.69M | -84.70M | -38.38M | -29.62M | -15.90M | -20.90M | 6.10M | 5.40M |
| Investing Activities | ||||||||||||||||||||||||||||
| Capital Expenditures | — | — | -23.40M | -10.90M | -14.70M | -24.80M | -6.93M | -4.10M | -1.93M | -1.57M | -505,000 | -939,000 | -505,000 | 21,000 | 1.16M | -727,000 | -495,000 | -3.11M | -7.24M | -53.15M | -13.80M | -5.30M | -3.81M | -2.44M | -2.10M | -3.70M | -6.40M | -2.30M |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | -42.70M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -1.41B | -628.90M | -804.70M | -735.50M | -866.10M | -545.90M | -583.41M | -298.78M | -449.05M | -257.54M | -145.33M | -166.31M | -139.10M | -89.79M | -16.80M | -36.99M | -94.64M | -64.04M | -382.83M | -593.72M | -448.29M | -401.59M | -175.89M | -151.58M | -87.70M | -41.60M | -113.10M | -85.20M |
| Sale of Investments | 972.40M | 511.00M | 697.90M | 750.50M | 669.70M | 327.80M | 339.09M | 415.83M | 255.12M | 154.13M | 151.28M | 132.52M | 134.28M | 34.84M | 27.62M | 82.13M | 117.13M | 186.91M | 399.97M | 645.05M | 300.49M | 360.87M | 163.05M | 78.35M | 68.60M | 50.00M | 112.30M | 38.90M |
| Investing Cash Flow | -438.80M | -160.60M | -130.20M | 4.10M | -279.96M | -242.90M | -250.87M | 112.86M | -195.81M | -105.37M | 5.34M | -34.76M | -3.53M | -54.70M | 12.06M | 44.42M | 20.84M | 120.28M | 9.38M | 18.47M | -186.65M | -46.02M | -16.64M | -75.67M | -21.20M | 4.70M | -7.20M | -49.30M |
| Financing Activities | ||||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | 502.78M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | -279.00M | -100,000 | -186.90M | — | — | — | — | — | — | — | — | — | — | — | -1.49M | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 236,000 | — | 104,000 | — | 15,000 | — | — | 100,000 | — |
| Financing Cash Flow | — | -558.00M | -200,000 | -373.80M | 27.31M | 29.53M | 516.65M | 2.39M | 276.99M | 138.73M | 5.30M | 83.70M | 286,000 | 21.48M | 9.90M | -1.45M | 591,000 | 15.85M | 16.97M | 7.00M | 196.61M | 3.56M | 179.49M | 93.38M | 41.00M | 400,000 | 800,000 | 47.50M |
| Other Cash Details | ||||||||||||||||||||||||||||
| End Cash Position | 259.10M | 270.70M | 344.00M | 190.30M | 115.50M | 147.20M | 259.21M | 88.15M | 74.20M | 31.01M | 44.79M | 63.75M | 50.11M | 54.05M | 37.33M | 68.47M | 99.66M | 80.98M | 49.95M | 61.03M | 105.85M | 44.31M | 163.89M | 21.08M | 21.30M | 11.70M | 15.80M | — |
| Income Tax Paid | 51.50M | 14.40M | 5.10M | 15.30M | 500,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 3.80M | 6.60M | 8.60M | 11.60M | 11.60M | 11.60M | 6.24M | — | — | — | — | — | — | — | — | 74,000 | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 361.60M | 322.90M | 233.10M | 217.60M | 132.30M | 76.60M | -101.27M | -110.29M | -39.93M | -48.75M | -30.15M | -36.27M | -1.45M | 49.63M | -53.13M | -75.49M | -59.96M | -102.44M | -38.03M | -153.14M | -13.31M | -84.67M | -25.66M | -21.09M | -12.40M | -14.40M | 4.60M | 4.40M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| iShares Core S&P Midcap ETF | Nov 30, 2024 | 3,243,015 | 494.30M | 3.20% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 3,204,584 | 488.44M | 3.17% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 2,527,816 | 385.29M | 2.50% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 1,512,278 | 230.50M | 1.49% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 1,512,170 | 230.48M | 1.49% |
| Vanguard Small-Cap Growth Index Fund | Sep 30, 2024 | 1,395,750 | 212.74M | 1.38% |
| SPDR S&P Mid Cap 400 ETF Trust | Nov 30, 2024 | 818,717 | 124.79M | 0.81% |
| Dodge & Cox Stock Fund | Sep 30, 2024 | 700,288 | 106.74M | 0.69% |
| iShares Biotechnology ETF | Nov 30, 2024 | 673,148 | 102.60M | 0.66% |
| iShares MSCI USA Min Vol Factor ETF | Nov 30, 2024 | 639,738 | 97.51M | 0.63% |
Article
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
On Thursday, Neurocrine Biosciences Inc. NBIX reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56.
Feb 7, 2025
Article
Neurocrine Biosciences Reports Mixed Q4
Neurological therapeutics specialist Neurocrine Biosciences (NBIX -0.46%) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted earnings per share (EPS) beat estimates significantly.
Feb 7, 2025
Article
Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Conference Call Participants Phil Nadeau - TD Cowen Paul Matteis - Stifel Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Cory Kasimov - Evercore David Amsellem - Piper Sandler Malcolm Kuno - JPMorgan Chris Shibutani - Goldman Sachs Marc Goodman - Leerink Partners Jeffrey Hung - Morgan Stanley Charlie Moore - Baird Mohit Bansal - Wells Fargo Ash Verma - UBS Sumant Kulkarni - Canaccord Myles Minter - William Blair Laura Chico - Wedbush Securities Ami Fadia - Needham Uy Ear - Mizuho Malcolm Hoffman - BMO Capital Markets Operator Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Q4 and Fiscal Year 2024 Earnings Call. [Operator Instructions] Please note today's call will be recorded, and I will be standing by should you need any assistance.
Feb 7, 2025
